Novo Nordisk Unveils Strategy For Dominating Diabetes Market In China
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk has carved out a dominant position in China's diabetic drug market despite launching only one oral hypoglycemic agent and insulin thanks to its 20-year presence in the country that allows the establishment of an extensive sales network. Its revenue is evenly split between key cities and periphery markets. The company's strategy is to actively conduct health education on diabetes in two areas, namely, mainstream patient education and physician training in communities. In addition, Novo Nordisk expects to make an official announcement this October about its plans to set up a plant in Tianjin that will supply products to China and more than 200 countries worldwide. (Click here for more - Chinese Language)
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.